Clinical Trials Logo

Clinical Trial Summary

This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma. The aim of this study was to observe and evaluate the efficacy and safety of Sintilimab combined with Anlotinib hydrochloride and platinum-containing dual-agent chemotherapy as first-line therapy in malignant pleural mesothelioma.


Clinical Trial Description

Patients with advanced or metastatic (stage IIIB or IV) pleural mesothelioma who had not received previous systemic therapy were screened for eligible subjects to be eligible for enrollment after signing an written informed consent to receive Sintilimab combined with Anlotinib hydrochloride and platinum-containing dual-agent chemotherapy until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other antineoplastic therapy, death or other situations for which protocol specified treatment should be discontinued (whichever occurs first). The maximum duration of treatment with Sintilimab is 24 months (in general). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05188859
Study type Interventional
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Wang, MD,PhD
Phone 8610-87788029
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date January 2022
Completion date January 2026

See also
  Status Clinical Trial Phase
Completed NCT02519049 - 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Terminated NCT02357147 - Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) Phase 2
Completed NCT02303899 - Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma Phase 2
Recruiting NCT03502746 - Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma Phase 2
Not yet recruiting NCT04823741 - Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma
Recruiting NCT03654833 - Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma Phase 2
Not yet recruiting NCT05136677 - A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants Phase 2
Recruiting NCT03546426 - Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies Phase 1
Recruiting NCT03393858 - Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma Phase 1/Phase 2
Completed NCT03068117 - Malignant Mesothelioma - Can we Improve Quality of Life N/A
Recruiting NCT03907852 - Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer Phase 1/Phase 2